Inito, a graduate of Y Combinator, specializes in aiding women to conveniently track fertility hormones from home. Recently, the company secured $6 million in Series A funding, primarily led by Fireside Ventures. Their fertility monitor and kit are tailored to provide users with straightforward fertility diagnostic outcomes directly on their mobile phones within a brief span of 10 minutes.

The Bengaluru-based startup, established in 2015 by CEO Aayush Rai and CTO Varun A Venkatesan, originated from their shared professional background at medtech giant Siemens. Rai, involved in product development, and Venkatesan, a researcher for medical products, fostered their connection through regular Sunday kayaking sessions. During these conversations, they envisioned making a meaningful impact on people's lives, which led them to leave their jobs and launch Inito. Their aim was to create tools enabling individuals to manage and comprehend their health from the comfort of their homes.

Unlike conventional at-home ovulation tests that predict fertile days by monitoring estrogen and Luteinizing hormone (LH), Inito sets itself apart by measuring the hormone crucial for confirming ovulation progesterone metabolite PdG, along with three other fertility hormones: estrogen, LH, and FSH all on a single test strip.

The Inito kit includes a monitor, test strips, and access to the Inito app. The monitor easily attaches to your smartphone and accurately reads high-density test strips. Upon registering your cycle history in the app, Inito prompts you to test on specific days and provides detailed step-by-step instructions. The testing process involves dipping the test strip in urine, attaching the monitor to your phone, and inserting the test strip into the monitor.